PE20220287A1 - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares - Google Patents
Anticuerpos anti-sema3a y sus usos para tratar enfermedades ocularesInfo
- Publication number
- PE20220287A1 PE20220287A1 PE2021001846A PE2021001846A PE20220287A1 PE 20220287 A1 PE20220287 A1 PE 20220287A1 PE 2021001846 A PE2021001846 A PE 2021001846A PE 2021001846 A PE2021001846 A PE 2021001846A PE 20220287 A1 PE20220287 A1 PE 20220287A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding fragment
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referido a un anticuerpo anti-Sema3A o un fragmento de fijacion al antigeno de este que comprende: una region variable de la cadena pesada que comprende la secuencia de aminoacidos de SEQ ID NO: 1 (H-CDR1); la secuencia de aminoacidos de SEQ ID NO: 2 (H-CDR2); y la secuencia de aminoacidos de SEQ ID NO: 3 (H-CDR3); y una region variable de la cadena liviana que comprende la secuencia de aminoacidos de SEQ ID NO: 4 (L-CDR1); la secuencia de aminoacidos de SEQ ID NO: 5 (L-CDR2); y la secuencia de aminoacidos de SEQ ID NO: 6 (L-CDR3). Este anticuerpo anti-Sema3A o un fragmento de fijacion al antigeno inhibe el efecto represor de vasos de semaforina 3A (SemaA3) para mejorar la revascularizacion de la retina. Tambien se refiere a un polinucleotido aislado, un vector de expresion que comprende dicho polinucleotido aislado, una celula huesped, un metodo para producir un anticuerpo anti-Sema3A, una composicion farmaceutica que comprende dicho anticuerpo o un fragmento de fijacion al antigeno y su uso en el tratamiento o prevencion de una enfermedad ocular o retiniana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19173454 | 2019-05-09 | ||
| PCT/EP2020/062802 WO2020225400A1 (en) | 2019-05-09 | 2020-05-08 | Anti-sema3a antibodies and their uses for treating eye or ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220287A1 true PE20220287A1 (es) | 2022-02-25 |
Family
ID=66476463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001846A PE20220287A1 (es) | 2019-05-09 | 2020-05-08 | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11267880B2 (es) |
| EP (1) | EP3966239A1 (es) |
| JP (2) | JP7314310B2 (es) |
| KR (1) | KR20220007128A (es) |
| CN (1) | CN113795509A (es) |
| AR (1) | AR122266A1 (es) |
| AU (1) | AU2020267874A1 (es) |
| BR (1) | BR112021019854A2 (es) |
| CA (1) | CA3137377A1 (es) |
| CL (1) | CL2021002795A1 (es) |
| CO (1) | CO2021014768A2 (es) |
| CR (1) | CR20210559A (es) |
| DO (1) | DOP2021000226A (es) |
| EA (1) | EA202193038A1 (es) |
| EC (1) | ECSP21082527A (es) |
| IL (1) | IL287758A (es) |
| JO (1) | JOP20210300A1 (es) |
| MA (1) | MA55872A (es) |
| MX (1) | MX2021013671A (es) |
| PE (1) | PE20220287A1 (es) |
| SA (1) | SA521430793B1 (es) |
| SG (1) | SG11202110842QA (es) |
| TW (1) | TWI836069B (es) |
| WO (1) | WO2020225400A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55872A (fr) | 2019-05-09 | 2022-03-16 | Boehringer Ingelheim Int | Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires |
| US20220127344A1 (en) * | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
| PE20240357A1 (es) * | 2021-03-30 | 2024-02-27 | Bayer Ag | Anticuerpos anti-sema3a y usos de los mismos |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| WO2011055550A1 (ja) | 2009-11-05 | 2011-05-12 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
| WO2013005603A1 (ja) * | 2011-07-01 | 2013-01-10 | 公立大学法人横浜市立大学 | 結膜におけるアレルギー性炎症の予防及び／又は治療剤 |
| DK2955195T3 (da) | 2013-02-06 | 2019-05-06 | Univ Yokohama City | Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme |
| AU2014221144B2 (en) | 2013-02-21 | 2018-03-22 | Rsem, Limited Partnership | Inhibition of Sema3A in the prevention and treatment of ocular hyperpermeability |
| PT3189074T (pt) | 2014-09-05 | 2021-04-19 | Rsem Lp | Composições e métodos para tratar e prevenir a inflamação |
| CN108290942B (zh) | 2015-10-27 | 2021-08-27 | 社会福祉法人三星生命公益财团 | 与人及小鼠信号素3a交联的抗体及其用途 |
| KR101854529B1 (ko) | 2015-10-27 | 2018-05-04 | (주) 팬젠 | 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도 |
| US10604571B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
| MA55872A (fr) | 2019-05-09 | 2022-03-16 | Boehringer Ingelheim Int | Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires |
-
2020
- 2020-05-08 MA MA055872A patent/MA55872A/fr unknown
- 2020-05-08 KR KR1020217040292A patent/KR20220007128A/ko unknown
- 2020-05-08 CN CN202080034499.1A patent/CN113795509A/zh active Pending
- 2020-05-08 TW TW109115394A patent/TWI836069B/zh active
- 2020-05-08 AR ARP200101337A patent/AR122266A1/es unknown
- 2020-05-08 BR BR112021019854A patent/BR112021019854A2/pt unknown
- 2020-05-08 MX MX2021013671A patent/MX2021013671A/es unknown
- 2020-05-08 EA EA202193038A patent/EA202193038A1/ru unknown
- 2020-05-08 JP JP2021565942A patent/JP7314310B2/ja active Active
- 2020-05-08 AU AU2020267874A patent/AU2020267874A1/en active Pending
- 2020-05-08 PE PE2021001846A patent/PE20220287A1/es unknown
- 2020-05-08 SG SG11202110842QA patent/SG11202110842QA/en unknown
- 2020-05-08 JO JOP/2021/0300A patent/JOP20210300A1/ar unknown
- 2020-05-08 CA CA3137377A patent/CA3137377A1/en active Pending
- 2020-05-08 CR CR20210559A patent/CR20210559A/es unknown
- 2020-05-08 US US16/869,618 patent/US11267880B2/en active Active
- 2020-05-08 WO PCT/EP2020/062802 patent/WO2020225400A1/en active Application Filing
- 2020-05-08 EP EP20723153.1A patent/EP3966239A1/en active Pending
-
2021
- 2021-10-25 CL CL2021002795A patent/CL2021002795A1/es unknown
- 2021-11-01 IL IL287758A patent/IL287758A/en unknown
- 2021-11-01 DO DO2021000226A patent/DOP2021000226A/es unknown
- 2021-11-02 CO CONC2021/0014768A patent/CO2021014768A2/es unknown
- 2021-11-09 SA SA521430793A patent/SA521430793B1/ar unknown
- 2021-11-18 EC ECSENADI202182527A patent/ECSP21082527A/es unknown
-
2022
- 2022-01-25 US US17/583,245 patent/US20220144929A1/en not_active Abandoned
-
2023
- 2023-07-12 JP JP2023114243A patent/JP2023130473A/ja active Pending
-
2024
- 2024-01-26 US US18/423,352 patent/US20240336674A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20210559A (es) | 2021-12-23 |
| US20200385446A1 (en) | 2020-12-10 |
| SA521430793B1 (ar) | 2024-03-28 |
| KR20220007128A (ko) | 2022-01-18 |
| DOP2021000226A (es) | 2021-12-15 |
| US11267880B2 (en) | 2022-03-08 |
| SG11202110842QA (en) | 2021-10-28 |
| MA55872A (fr) | 2022-03-16 |
| JOP20210300A1 (ar) | 2023-01-30 |
| CL2021002795A1 (es) | 2022-08-05 |
| JP7314310B2 (ja) | 2023-07-25 |
| US20220144929A1 (en) | 2022-05-12 |
| TW202108621A (zh) | 2021-03-01 |
| TWI836069B (zh) | 2024-03-21 |
| AR122266A1 (es) | 2022-08-31 |
| US20240336674A1 (en) | 2024-10-10 |
| JP2023130473A (ja) | 2023-09-20 |
| CN113795509A (zh) | 2021-12-14 |
| EA202193038A1 (ru) | 2022-03-30 |
| JP2022531698A (ja) | 2022-07-08 |
| EP3966239A1 (en) | 2022-03-16 |
| IL287758A (en) | 2022-01-01 |
| MX2021013671A (es) | 2021-12-10 |
| CO2021014768A2 (es) | 2021-11-19 |
| AU2020267874A1 (en) | 2021-10-28 |
| CA3137377A1 (en) | 2020-11-12 |
| BR112021019854A2 (pt) | 2022-02-15 |
| ECSP21082527A (es) | 2021-12-30 |
| WO2020225400A1 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220287A1 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
| PE20080036A1 (es) | Anticuerpos humanos para la interleucina-13 (il13) | |
| AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| ES2653664T3 (es) | Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano | |
| PE20080112A1 (es) | Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas | |
| AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| BR112018002877A2 (pt) | anticorpos anti-receptor ccr7 humanizados | |
| NZ599438A (en) | Humanized antibodies against human il-22ra | |
| PE20200173A1 (es) | Anticuerpos anti-trkb | |
| AR105541A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh | |
| RU2022101369A (ru) | Анти-met антитела и их использование | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| RU2017105596A (ru) | Антитела к церамиду | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| ECSP22015044A (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| PE20231029A1 (es) | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO | |
| AR115192A1 (es) | Anticuerpos | |
| PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| CO2024007361A2 (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| EA201990613A1 (ru) | Антитела против гремлина-1 (grem1) и способы их применения для лечения легочной артериальной гипертензии |